Topic: TCGA and cholangiocarcinoma
TCGA (The Cancer Genome Atlas) is a collaboration jointly supported and managed by the National Cancer Institute and the National Human Genome Research Institute, both parts of the National Institutes of Health. This program involves investigators aiming to improve the understanding of the molecular driver of specific tumor types.
TCGA has chosen cancers for study based on specific criteria that include:
Poor prognosis and overall public health impact
Availability of human tumor and matched-normal tissue samples that meet TCGA standards for patient consent, quality and quantity
We are fortunate, sufficient tumor tissue had been submitted and our cancer has been accepted in this program.
This is the latest press release regarding cholangiocarcinoma:
Researchers with The Cancer Genome Atlas (TCGA) Research Network performed an integrated molecular analysis of 38 cholangiocarcinoma tumors, rare cancers that originate in the body’s bile ducts. Cholangiocarcinoma is associated with a poor prognosis because it is often diagnosed at an advanced stage and does not respond well to conventional chemotherapies. The new study, published in Cell Reports on March 14, 2017, reveals features of the disease that could lead to new therapeutic opportunities.